EVMN Stock Forecast: Evommune, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$7.04
−2.76% on the day

The median 12-month analyst price target for Evommune, Inc. is $22. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$291.1M
Ticker Nerd rank
11/ 100
Median analyst target
$22
Analysts covering
12
Revenue$0.0
Operating income−$34.9M
Net income−$32.2M
Free cash flow−$20.5M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.7%
1M
+30.9%
YTD
−58.9%
1Y
−62.4%
From 52W high
−77.7%
From 52W low
+38.0%
$5
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Evommune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
11/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
63
Value
36
Quality
36
Revisions
32
Accruals
22
Volatility
21
Growth
10
Momentum
1

Issuance (63): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EVMN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EVMN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26EVMNHigh $28Median $22Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
9
Buy
3
Hold
0
Sell
$8
Low
$22
Median
$28
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
13 Nov 2026NeedhamMaintainsBuy$28 → $25
12 Oct 2026UBSInitiatesNeutral$8.00
9 Sept 2026HC Wainwright & Co.ReiteratesNeutral—
9 Sept 2026Leerink PartnersMaintainsOutperform$28 → $22
9 Sept 2026RBC CapitalMaintainsOutperform$29 → $21
26 Aug 2026NeedhamInitiatesBuy$28
7 Aug 2026RBC CapitalMaintainsOutperform$30 → $29
3 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
30 June 2026HC Wainwright & Co.DowngradeNeutral—
30 June 2026Morgan StanleyMaintainsOverweight$55 → $26
29 June 2026William BlairDowngradeMarket Perform—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
11 May 2026Morgan StanleyMaintainsOverweight—
10 Apr 2026RBC CapitalReiteratesOutperform—
18 Mar 2026Clear StreetInitiatesBuy—
18 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Feb 2026HC Wainwright & Co.MaintainsBuy—
22 Jan 2026OppenheimerInitiatesOutperform—
8 Jan 2026Raymond JamesInitiatesStrong Buy—
6 Jan 2026HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EVMN.

Market Radar

This page is one stock. Monday covers all of them.

EVMN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EVMN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Evommune, Inc. returned −62.4% against +6.9% for the S&P 500, dividends included.

EVMN vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150Jan 26Apr 26Jul 26Oct 26EVMNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EVMN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
22.4×

Cheaper than 7% of US stocks

Price / book
1.0×

Cheaper than 70% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−69.5%

Higher than 18% of US stocks

Return on assets
−42.0%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Evommune, Inc. has a market value of $291.1M and an enterprise value of $130.7M.

  • Revenue in the twelve months to 30 June 2026: $10.0M.

  • Net income over the same four quarters: −$94.7M, a −946.7% net margin.

  • Diluted earnings per share, trailing twelve months: −$3.37.

  • Free cash flow in the twelve months to 30 June 2026: −$74.7M.

  • Shares outstanding: 36.3M.

  • Evommune, Inc. employs 48 people — $208K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

EVMN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EVMNEvommune, Inc.$291.1M11
BNTCBenitec Biopharma, Inc.$285.9M39
XFORX4 Pharmaceuticals, Inc.$297.4M65
SPRYARS Pharmaceuticals, Inc.$297.6M13
GLSIGreenwich LifeSciences, Inc.$282.6M53
FULCFulcrum Therapeutics, Inc.$281.5M35
RLMDRelmada Therapeutics, Inc.$274.8M55

Take a look at EVMN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Evommune, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about EVMN

What is the EVMN stock price forecast for 2026-2027?

The median 12-month analyst price target for Evommune, Inc. is $22, with estimates ranging from $8 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EVMN stock a buy right now?

Of the 12 analysts covering Evommune, Inc., 9 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evommune, Inc. 11 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EVMN?

As at 21 Nov 2026, Evommune, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (63 of 100).

Will EVMN stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts is $22, and Ticker Nerd's factor model ranks Evommune, Inc. 11 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EVMN stock forecast for 2030?

No analyst covering Evommune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $28 over the next 12 months.

How has EVMN stock performed over the past year?

Evommune, Inc. returned -62.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Evommune, Inc. do?

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing novel treatments designed to address key drivers of inflammation, with current programs centered on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.

Company

About Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing novel treatments designed to address key drivers of inflammation, with current programs centered on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its pipeline includes product candidates such as EVO756 and EVO301, which are being developed to target immune pathways involved in these conditions. Evommune’s work is positioned within the broader immunology and inflammation markets, where it aims to support more precise treatment options for patients with persistent inflammatory disorders. Based in Palo Alto, California, Evommune emphasizes research-driven drug development across small-molecule and biologic approaches.

CEO Mr. Luis C. Pena · 48 employees · United States · https://www.evommune.com